Clearmind Medicine Inc. (NASDAQ: CMND) announced it has signed a research agreement with Yissum Research Development Company of the Hebrew University of Jerusalem to fund a preclinical study examining MEAI in combination with tirzepatide for obesity treatment.

The 12-month study will evaluate the metabolic effects of MEAI (CMND-100) when used alongside tirzepatide and as a maintenance therapy following tirzepatide treatment in diet-induced obese mice. Professor Joseph Tam and his team at the Obesity and Metabolism Laboratory at Hebrew University will conduct the research.

The study aims to examine potential additive effects when MEAI is administered with tirzepatide and assess MEAI's ability to reduce weight regain after tirzepatide discontinuation. Previous research showed MEAI achieved approximately 15-20% body weight reduction in obese mice through increased energy expenditure while preserving lean mass.

The incretin-based therapy market, which includes tirzepatide, was valued at approximately $50-66 billion in 2025 and is projected to reach $170-185 billion by 2033. Current GLP-1 and dual GLP-1/GIP receptor agonists work primarily by suppressing appetite, but patients often experience substantial weight regain of 25% or more within one year of discontinuation.

"MEAI is designed to offer a differentiated mechanism that potentially complements incretin therapies," said Dr. Adi Zuloff-Shani, Chief Executive Officer of Clearmind Medicine. "While those drugs excel at reducing food intake, our previous preclinical data show MEAI significantly enhances energy expenditure."

Clearmind is a clinical-stage biotech company focused on developing non-hallucinogenic neuroplastogen-derived therapeutics. The company holds 19 patent families, including 31 granted patents.